Aura Biosciences, (id:6616 AURA)

8.95 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:38:31 PM)

Exchange closed, opens in 1 day 10 hours

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Aura Biosciences,

Market Capitalization 512.43M

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.